# Daewoong Pharmaceutical Co. LTD. clinical trials: 200 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 200 trials with Daewoong Pharmaceutical Co. LTD. as lead sponsor, 20 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Daewoong Pharmaceutical Co. LTD.: 200 rows for $10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/daewoong-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 200
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 25 newest of 200, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 25, 2026 | NCT07783763 | Study of DWP450 in Japanese Subjects With Glabellar Lines | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Not yet recruiting | Glabellar Lines | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783763) |
| August 5, 2026 | NCT07746518 | Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Not yet recruiting | Healed Erosive Esophagitis | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746518) |
| July 28, 2026 | NCT07730138 | Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Not yet recruiting | Gastric Ulcer | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730138) |
| June 2, 2026 | NCT07619833 | To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and... | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus) | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619833) |
| April 30, 2026 | NCT07558707 | Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice | Daewoong Pharmaceutical Co. LTD. | Observational | Not yet recruiting | Peptic Ulcer, NSAID-Induced Peptic Ulcer | 7,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558707) |
| April 20, 2026 | NCT07539415 | A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult... | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Obesity & Overweight, Type 2 Diabetes | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539415) |
| April 16, 2026 | NCT07533266 | Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer | Daewoong Pharmaceutical Co. LTD. | Phase 4 | Not yet recruiting | NSAID (Non-Steroidal Anti-Inflammatory Drug) | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533266) |
| April 8, 2026 | NCT07516977 | Noseguard for Prevention of Respiratory Infections in Real-World Use | Daewoong Pharmaceutical Co. LTD. | Not applicable | Not yet recruiting | Respiratory Infection Virus, COVID-19, Influenza | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516977) |
| April 7, 2026 | NCT07515599 | Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension | Daewoong Pharmaceutical Co. LTD. | Observational | Recruiting | Stage 1 Hypertension | 12,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515599) |
| April 7, 2026 | NCT07515560 | Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study | Daewoong Pharmaceutical Co. LTD. | Observational | Not yet recruiting | Dyslipidemia | 12,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515560) |
| January 27, 2026 | NCT07371104 | Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Cancer, Ovarian Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371104) |
| December 5, 2025 | NCT07267221 | Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition. | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07267221) |
| December 3, 2025 | NCT07260851 | Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting... | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260851) |
| December 1, 2025 | NCT07256600 | PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Completed | Healthy Subjects | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07256600) |
| October 8, 2025 | NCT07213310 | Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213310) |
| September 24, 2025 | NCT07190391 | Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis | Daewoong Pharmaceutical Co. LTD. | Observational | Not yet recruiting | Psoriasis | 425 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190391) |
| August 27, 2025 | NCT07144176 | PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Healthy Subjects | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144176) |
| June 10, 2025 | NCT07013279 | Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Not yet recruiting | Glabellar Lines | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07013279) |
| April 29, 2025 | NCT06948487 | Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis | Daewoong Pharmaceutical Co. LTD. | Observational | Recruiting | Gastritis | 12,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948487) |
| March 10, 2025 | NCT06866509 | To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients | Daewoong Pharmaceutical Co. LTD. | Observational | Completed | Dyslipidemia | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06866509) |
| December 27, 2024 | NCT06751121 | Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Completed | Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects | 461 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751121) |
| December 16, 2024 | NCT06736587 | Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Autoimmune Diseases | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736587) |
| November 12, 2024 | NCT06682000 | Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Completed | Hypertension, Essential Hypertension | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06682000) |
| November 4, 2024 | NCT06671392 | A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension | Daewoong Pharmaceutical Co. LTD. | Phase 3 | Completed | Essential Hypertension | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06671392) |
| October 31, 2024 | NCT06668506 | To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis | Daewoong Pharmaceutical Co. LTD. | Observational | Completed | Gastritis | 2,814 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06668506) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 97 |
| Phase 2 | 8 |
| Phase 2/3 | 3 |
| Phase 3 | 50 |
| Phase 4 | 14 |
| Not applicable | 3 |
| Observational | 25 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 103 |
| Unknown | 59 |
| Not yet recruiting | 11 |
| Recruiting | 9 |
| Active not recruiting | 8 |
| Terminated | 7 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 19 |
| Dyslipidemias | 12 |
| Hypertension | 11 |
| COVID-19 | 5 |
| Idiopathic Pulmonary Fibrosis | 4 |
| Gastritis | 4 |
| Gastroesophageal Reflux | 3 |
| Hyperlipidemias | 3 |
| Peptic Ulcer | 3 |
| Puberty, Precocious | 2 |
| Stomach Neoplasms | 2 |
| Essential Hypertension | 2 |
| Hepatitis B, Chronic | 2 |
| Fatigue | 2 |
| Metabolic Syndrome | 1 |
| Blepharospasm | 1 |
| Esophagitis, Peptic | 1 |
| Obesity | 1 |
| Overweight | 1 |
| Dwarfism, Pituitary | 1 |
| Diarrhea | 1 |
| Arthritis, Rheumatoid | 1 |
| Diabetes Mellitus | 1 |
| Glucose Metabolism Disorders | 1 |
| Metabolic Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Oncology practices in the United States](https://specstream.ai/data/businesses/oncology-practices/united-states)
